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Abstract
Background: The Friedewald formula (LDL-F) for the estimation of low-density lipoprotein (LDL)
cholesterol concentrations is the most often used formula in clinical trials and clinical practice.
However, much concern has been raised as to whether this formula is applicable in all patient
populations such as the presence of chylomicronaemia and/or hypertriglyceridaemia. The aim of
the present study was to evaluate various LDL cholesterol calculation formulas as well as LDL
cholesterol levels provided by the Lipoprint LDL System (LDL-L) in patients with the metabolic
syndrome (MetSyn).
Results: LDL-F showed significant differences from other formulas in the total cohort, as well as
in MetSyn individuals. This was not the case in nonMetSyn subjects, where LDL-F did not differ with
other formulas, with the exception of one formula (LDL by Planella, LDL-P). The bias between
LDL-F and other LDL estimation formulas were significantly higher in MetSyn subjects compared
to nonMetSyn individuals, except for LDL-L which produced similar bias with LDL-F in both study
groups.
Conclusion: LDL-F seems to exhibit some limitations as far as the calculation of LDL-C levels in
patients with the MetSyn is concerned. LDL-L might be more accurate in MetSyn subjects, but so
far its use is limited for the estimation of small, dense LDL (sdLDL) cholesterol levels and mean
LDL particle size for research purposes only.
Background
The association between total cholesterol (TC) and the
risk of atherosclerotic disease is well established by many
studies, such as the Framingham Heart Study [1]. Low-
density lipoprotein (LDL) particles are the main carriers of
the circulating cholesterol and they play a key role in cho-
lesterol transfer and metabolism [2]. The Third Report of
the National Cholesterol Education Program (Adult Treat-
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ment Panel III) (NCEP ATP III) guidelines focus on LDL-
cholesterol (LDL-C) levels as the primary target of choles-
terol-lowering therapy [3]. Friedewald formula is the most
often used formula for the calculation of LDL-C levels in
clinical trials [4]. However, much concern has been raised
as to whether this formula is applicable in all patient
groups [5].
The principle of the Friedewald formula (LDL-F) is based
on two assumptions: Firstly, that since very low-density
lipoprotein (VLDL) carries most of the circulating triglyc-
erides (TG), VLDL-cholesterol (VLDL-C) can be estimated
reasonably well as TG concentrations divided by constant
(i.e. 5 for mg/dL and 2.2 for mmol/L) [2,5]. Secondly, that
TC is distributed among the three major lipoprotein sub-
classes [namely high-density lipoprotein (HDL), LDL and
VLDL] [2]. There are though some limitations as to the
calculation of LDL-C according to the LDL-F formula, the
two most common being that the patient needs to be fast-
ing for at least 12 hours and that TG levels have to be <400
mg/dL [6].
Metabolic syndrome (MetSyn) comprises a clustering of
atherosclerotic factors, including abdominal obesity, dys-
lipidemia, disturbed carbohydrate metabolism, and
hypertension [7]. The NCEP ATP III criteria for the diag-
nosis of the MetSyn are as follows: waist circumference
>102 cm in men and >88 cm in women, TG ≥ 150 mg/dL,
high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL
in men and < 50 mg/dL in women, fasting glucose ≥ 110
mg/dL and blood pressure ≥ 130/85 mm Hg (or use of
antihypertensive agents) (three of the previously men-
tioned criteria are required for the diagnosis of the Met
Syn) [3]. Data from the ATTICA and the METS-GREECE
studies showed that the overall prevalence of the MetSyn
in the Greek population is 19.8% and 23.6%, respectively
[8-10]. The most common lipid abnormalities associated
with the MetSyn are elevated TG levels, low HDL-C levels
and the existence of small dense LDL (sdLDL) particles
[11]. SdLDL particles are thought to be more atherogenic
than large, buoyant particles [12,13]. Large clinical studies
have shown a consistent association between sdLDL par-
ticles and incident atherosclerotic disease [14,15].
The purpose of the present study was to evaluate the accu-
racy of various formulas for the calculation of LDL-C lev-
els in patients with the MetSyn.
Results
Of the total cohort, 105 subjects fulfilled the NCEP ATP III
MetSyn criteria, whereas 74 individuals did not. As shown
in Table 1, MetSyn subjects exhibited higher levels of TC,
TRG, and apoB and lower HDL-C and apoA-I levels com-
pared to individuals not fulfilling the criteria for the diag-
nosis of MetSyn.
Table 2 shows the estimation of LDL-C according to vari-
ous formulas in the total cohort, as well as in MetSyn and
nonMetSyn subjects. LDL-C levels were significantly but
borderline different between the two study groups when
LDL-C was calculated according to the formulas proposed
by Friedewald (LDL-F) and by Hattori (LDL-H) (p = 0.04
for both comparisons), whereas it was significantly differ-
ent when it was calculated according to the formula used







TC (mg/dL) 229 ± 43 238 ± 45 218 ± 37*
TG (mg/dL) 162 ± 82 196 ± 77 113 ± 62*
HDL-C (mg/dL) 52 ± 11 49 ± 10 57 ± 12*
apoA-I (mg/dL) 138 ± 25 131 ± 25 148 ± 22*
apoB (mg/dL) 104 ± 26 109 ± 27 96 ± 24*
TC: total cholesterol, TG: triglycerides, HDL-C: high-density 
lipoprotein cholesterol, apo: apolipoprotein
Data represent mean ± SD.
*p ≤ 0.001 compared to MetSyn subjects.
Table 2: LDL-cholesterol concentrations calculated according to various formulas in the total cohort, as well as in MetSyn and 
nonMetSyn subjects
LDL-C estimated Total (n = 179) MetSyn (n = 105) nonMetSyn (n = 74) p (between MetSyn and 
nonMetSyn subjects)
LDL-F 145 ± 35 149 ± 38 138 ± 28 0.04
LDL-P 129 ± 29* 132 ± 32* 126 ± 26** NS
LDL-H 136 ± 33** 140 ± 36 130 ± 27 0.04
LDL-A 145 ± 41 154 ± 44 132 ± 33 0.001
LDL-W 138 ± 30 140 ± 33 136 ± 26 NS
LDL-L 133 ± 31* 135 ± 30** 130 ± 32 NS
Data are expressed as mean ± SD.
LDL: low-density lipoprotein, MetSyn: metabolic syndrome, LDL-F: LDL-cholesterol by Friedewald, LDL-P: LDL-cholesterol by Planella, LDL-H: 
LDL-cholesterol by Hattori, LDL-A: LDL-cholesterol by AMORIS, LDL-W: LDL-cholesterol by Wagner, LDL-L: LDL-cholesterol by the Lipoprint 
LDL system. One-way analysis of variance (ANOVA) followed by Least Significance Difference (LSD) for paired comparisons *p < 0.001, **p ≤ 0.01 
compared to LDL-F.Lipids in Health and Disease 2006, 5:8 http://www.lipidworld.com/content/5/1/8
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in AMORIS study (LDL-A) (p = 0.001). It should be noted
that no differences were detected between MetSyn and
nonMetSyn subjects when LDL-C was calculated accord-
ing to the formulas proposed by Planella and Wagner
(LDL-P and LDL-W, respectively) and when LDL-C levels
were provided by the Lipoprint System (LDL-L). When
LDL-C estimations were adjusted for TG levels (to avoid
the confounding effect of TG on LDL determination), no
differences were observed between MetSyn and nonMet-
Syn groups for any LDL-C estimation formula (data not
shown).
Additionally, in the total cohort significant differences
were found between LDL-C estimations (overall p <
0.001). Specifically, as shown in Table 2, LDL-F was signif-
icantly higher than LDL-P, LDL-H and LDL-L (p < 0.001,
= 0.01 and <0.001, respectively). In the MetSyn group, sig-
nificant differences were also observed between various
LDL-C estimations (overall p < 0.001), due to the differ-
ences observed between LDL-F and LDL-P (p < 0.001) and
LDL-F and LDL-L (p < 0.01) (Tables 2 and 3). Interest-
ingly, in the nonMetSyn group the only difference
observed was between LDL-F and LDL-P (p < 0.01)
(Tables 2 and 3).
Table 3 shows the biases (absolute values and percent-
ages) observed between LDL-F and all other LDL estima-
tions. The biases between LDL-F and all other LDL-C
estimations were different between MetSyn and nonMet-
Syn subjects except for LDL-L which did not differ
between the two study groups (Table 3).
We subsequently evaluated the correlation coefficients
between the various LDL formulas in the total cohort, as
well as within each study group (data not shown). All cor-
relations were statistically significant in all study groups
(p < 0.001 for all correlations), but there were some dis-
crepancies between formulas. LDL-L in the total cohort
showed the least correlation with all other formulas (Pear-
son's r ranged between 0.707 and 0.787, whereas all other
r were above the value of 0.83) (data not shown).
Finally we estimated the predictive power of the ratio
LDL-H/LDL-apoB to identify individuals with decreased
mean LDL particle size. We used as cut-off point the value
of 268Å of mean LDL particle size to identify subjects with
decreased LDL size, according to the manufacturer's
instructions. Hattori et al proposed that a value of 1.2 or
less of the LDL-H/LDL-apoB ratio postulates the prepon-
derance of sdLDL particles. Interestingly, the sensitivity
and specificity of this ratio to identify individuals with
decreased mean LDL particle size were 2.6% and 96.9%,
respectively and the positive and negative predictive val-
ues were 60% and 36.2%, respectively (data not shown).
Discussion
The association between elevated LDL-C levels and
increased risk of atherosclerotic disease has been clearly
demonstrated. Currently, most clinical laboratories and
clinical studies use the Friedewald formula for the estima-
tion of LDL-C levels, since the reference method, i.e. β-
quantification by ultracentrifugation, is not suitable for
routine use [4,6]. However, the accuracy of Friedewald
formula has been questioned in many patient groups,
such as patients with hypertriglyceridaemia [5], with type
III hyperlipidaemia [2], as well as in patients with second-
ary hyperlipidaemias, such those observed in patients
with diabetes mellitus, renal disease, hepatic failure, as
well as those on hormone replacement therapy [6,16,17].
These conditions are characterized not only by increased
TG levels but also by lipoprotein alterations, indicating
that the acceptable reliability of the LDL-F formula at TG
concentrations of 200–400 mg/dL needs special concern
in selected patient populations [2].
Dyslipidaemia is a hallmark of the MetSyn. The underly-
ing mechanism of the dyslipidaemia of the MetSyn is the
altered metabolism of TG-rich lipoproteins, such as VLDL
and IDL remnants [7,11]. Except for being a major com-
ponent of MetSyn, elevated TG levels are also very com-
mon in the general population [18]. This finding
strengthens the need of a formula for the estimation of
LDL-C levels that is applicable in individuals with raised
TG levels.
The present study is -to our knowledge- the first study to
evaluate various LDL-C calculation formulas in subjects
Table 3: Mean differences between LDL-F and other LDL-C 
estimations in the total cohort, as well as in MetSyn and 
nonMetSyn individuals.







(LDL-F) – (LDL-P) 14 (-16–64) 16 (-16–64) 13 (-6–27)*
10 (-13–33) 11 (-13–33) 9 (-5–18)**
(LDL-F) – (LDL-H) 9 (3–16) 10 (3–16) 8 (6–13)*
6 (3–7) 6 (6–7) 6 (6–7)*
(LDL-F) – (LDL-A) 0.5 (-48–28) -4 (149-28) 8 (-27-24)*
0.5 (-31–35) -3 (-31–35) 6 (-26-20)*
(LDL-F) – (LDL-W) 4 (-30–62) 7 (-30–62) 3 (-17–18)*
3 (-25–33) 4 (-25–33) 3 (-16-11)**
(LDL-F) – (LDL-L) 16 (-48–70) 14 (-47–70) 16 (-48–51)
10 (-48-37) 9 (-47-37) 12 (-48-33)
Data are expressed as median (range).
LDL: low-density lipoprotein, MetSyn: metabolic syndrome, LDL-F: 
LDL-cholesterol by Friedewald, LDL-P: LDL-cholesterol by Planella, 
LDL-H: LDL-cholesterol by Hattori, LDL-A: LDL-cholesterol by 
AMORIS, LDL-W: LDL-cholesterol by Wagner, LDL-L: LDL-
cholesterol by Lipoprint LDL system. Mann-Whitney U test *p < 0.01 
and **p < 0.05 compared to MetSyn individuals.Lipids in Health and Disease 2006, 5:8 http://www.lipidworld.com/content/5/1/8
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with the MetSyn. Moreover, a new LDL-C estimation is
presented for the first time, i.e. LDL-L.
The estimation of LDL-C levels according to LDL-L
method showed in the total population a mean difference
with LDL-F [16(-48–70) mg/dL] approaching the previ-
ously reported difference between LDL-F and LDL meas-
ured by ultracentrifugation (LDL-UC) ranging between
6.8 ± 13.3 mg/dL and 13.5 ± 13.9 mg/dL [6,16,17]. More-
over, the difference observed between LDL-F and LDL-P,
as well as between LDL-F and LDL-H in the total cohort
[14(-15–64) mg/dL and 9(3–16) mg/dL, respectively]
approached the difference observed between LDL-F and
LDL-L. This finding indicates that these methods for the
estimation of LDL-C levels may approach the accuracy of
the gold standard method for the evaluation of LDL-C lev-
els, i.e β-quantification by ultracentrifugation. In MetSyn
subjects the bias between LDL-F and LDL-L was 9(-47-
37)% and between LDL-F and LDL-P it was 11(-13–33)%,
whereas the corresponding differences in the nonMetSyn
group were 12(-48-34)% and 9(-5–19)% respectively.
Moreover, the bias between LDL-F and LDL-H was 10(3–
16) mg/dL in the MetSyn group and 8(6–13) mg/dL in the
nonMetSyn group. The bias between LDL-F and LDL-L did
not differ between MetSyn and nonMetSyn subjects while
the biases between LDL-F and LDL-P and LDL-F and LDL-
H were higher in the MetSyn group compared to the non-
MetSyn group.
ApoB levels are representative of the number of apoB con-
taining particles, even if alterations of their lipid content
is present, as occurs in subjects with elevated sdLDL parti-
cles [17]. This pattern is often seen in patients with diabe-
tes mellitus, with the MetSyn as well as in patients with
elevated TG levels, even if LDL-C concentrations are rela-
tively low [7,11]. Moreover, it has been proposed that
individuals exhibiting TG>133 mg/dL- a value within the
normal range of TG- usually have an abnormal abun-
dance of sdLDL particles [19]. The NCEP ATP III guide-
lines for the diagnosis of the MetSyn use as one of the
criteria the cut-off point of 150 mg/dL for TG concentra-
tion [3]. Therefore, MetSyn subjects, especially those with
raised TG levels, might exhibit abnormal abundance of
sdLDL particles. Consequently, the inclusion of apoB lev-
els in the calculation of LDL-C could provide a better esti-
mate of LDL-C concentration compared to LDL-F in
patients with sdLDL particles. Wagner et al evaluated the
accuracy of an apoB-based formula (LDL-W) in type 2 dia-
betic patients and found that this formula exhibited a bias
of -0.5 ± 6.1% against LDL-UC, significantly lower than
the bias of LDL-F against LDL-UC (-3.1 ± 6.4%) [20]. The
mean difference between LDL-W and LDL-F in the study
by Wagner et al was about 1.9 mg/dL, in favor of LDL-W.
Our data showed a mean difference between the two
equations of about 4.(-30–62) mg/dL in the total cohort,
and 7(-30–62) mg/dL and 3(-17–18) mg/dL in MetSyn
and nonMetSyn subjects, respectively, in favor of LDL-F.
This finding may be explained by the different study pop-
ulations (diabetic versus MetSyn and nonMetSyn sub-
jects). However, according to the results of the present
study, LDL-W did not differ from LDL-F estimation in any
study group.
Another study that evaluated LDL-C using an apoB-based
formula was that of Planella et al [21]. Planella et al pro-
posed a formula that, according to the results of their
study, produces an estimate of LDL-C that better
approaches true LDL-C concentrations obtained by ultra-
centrifugation compared to Friedewald formula, even in
patients with IV dyslipidaemia [21]. Our results showed
that LDL-P produced an LDL-C estimate that had a mean
difference of 14(-16–64) mg/dL, 16(-16–64) mg/dL and
13(-6–27) mg/dL, in the total cohort, in MetSyn and in
nonMetSyn groups, respectively, in favor of LDL-F.
LDL-P and LDL-W formulas, which take into account
apoB levels, as well as LDL-L, which directly measures the
cholesterol of all IDL and LDL subclasses, did not produce
different results in MetSyn and nonMetSyn subjects.
Moreover, LDL-F was significantly different from LDL-P
and LDL-L in the MetSyn group but differed only from
LDL-P in the nonMetSyn group. Though our results show
that there are not any discrepancies between LDL-P and
LDL-L estimations, LDL-L is not suitable for routine use,
since it is based on a method that is intended for research
use only so far and specifically for the estimation of
sdLDL-cholesterol, as well as for the measurement of
mean LDL particle size. This finding and the fact that LDL-
L was the only LDL-C estimation formula that did not pro-
duce different biases in MetSyn and nonMetSyn individu-
als (while all other formulas produced greater biases in
the MetSyn group compared to nonMetSyn group), indi-
cate that none of the currently existing formulas for LDL-
C estimation produces accurate results for LDL-C levels in
patients with -even mildly- elevated TG levels, as the Met-
Syn group in the present study. Consequently, it appears
that since the reference method (i.e. β-quantification via
UC) is expensive, time-consuming and requires special
equipment as well as trained personnel for its conduction,
that accurate direct methods for the determination of
LDL-C levels are required, especially in populations with
abnormal lipid and lipoprotein profile.
Finally, we examined the predictive value of the LDL-H/
LDL-apoB, proposed by Hattori et al for the evaluation of
LDL particle size [22]. According to the results of the
present study and using the proposed cut-off point of 1.2
for the above mentioned ratio, the ratio LDL-H/LDL-apoB
did not appear to be a sensitive marker of decreased mean
LDL particle size, as obtained by Lipoprint LDL System. ItLipids in Health and Disease 2006, 5:8 http://www.lipidworld.com/content/5/1/8
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should be noted that the normal range of LDL-H/LDL-
apoB ratio was derived from a small number of control
individuals in the study by Hattori et al.
Conclusion
Conclusively, the Friedewald formula seems to exhibit
some limitations as far as the estimation of LDL-C levels
is concerned in patients with the MetSyn. LDL-C levels
evaluated by Lipoprint LDL System seem more accurate
than other LDL estimation formulas in these patients,
since its difference to LDL-F approaches that of the refer-
ence method for LDL-cholesterol calculation, i.e. β-quan-
tification. However, Lipoprint LDL System is not
applicable to every day clinical practice and its intended
use is not for LDL-C estimation. Subsequent research
including β-quantification by ultracentrifugation valida-
tion is required in order to explore the accuracy of other
LDL-C estimation formulas as well as the accuracy of
direct methods for LDL-C measurement in patients with




One hundred and seventy-nine patients attending the
Outpatient Lipid Clinic of the University Hospital of Ioan-
nina participated in the present study. Exclusion criteria
were: prior atherosclerotic disease (myocardial infarction,
unstable angina, ischemic stroke, peripheral arterial dis-
ease, percutaneous transluminal coronary angioplasty
and coronary artery bypass graft), known diabetes melli-
tus (fasting glucose ≥ 126 mg/dL), liver disease (serum
aminotranferase activity greater than 3-fold, e.g. >120 IU/
L, normal range 5–40 IU/L), renal disease (serum creati-
nine levels greater than 15 mg/L, normal range 6–12 mg/
L), hypothyroidism (TSH greater than 5 µIU/ml, normal
range 0.5–4.8 µIU/mL). Moreover, patients receiving
drugs that could affect lipid metabolism as well as renal or
hepatic function were also excluded from the present
study. The diagnosis of the MetSyn was based on the
NCEP ATP III criteria [3]. The Ethics Committee of the
University Hospital of Ioannina gave its approval for the
conduction of the study and every participant gave written
consent.
Biochemical parameters
All lipid and lipoprotein determinations were carried out
after an overnight fast. Serum levels of TC, HDL-C, and TG
were determined enzymatically with an Olympus AU600
automated analyzer (Olympus Diagnostica, Hamburg,
Germany). Apolipoproteins (apo) A-I and B were meas-
ured with a DADE Behring Nephelometer BN100 (Lieder-
bach, Germany) in total serum. The calculation of LDL-C
was conducted according to the following equations:
Friedewald (LDL-F) [4]
LDL-F = TC - HDL-C - TG/5 (in mg/dL), excluding patients
with TG concentrations ≥ 400 mg/dL.
Planella (LDL-P), which focuses on the inclusion of apoB
levels in the estimation of LDL-C levels [21]
LDL-P = 0.41*TC - 0.14*TG + 0.66*apoB - 10.43 (in mg/
dL).
Hattori  (LDL-H), an equation very similar to that pro-
posed by Friedewald [22]
LDL-H = 0.94*TC - 0.94*HDL-C -0.19*TG (in mg/dL).
AMORIS study (LDL-A), including apoA-I levels in the
equation for LDL-C estimation [24]
LDL-A = 18.53 + 0.99*TC - 0.1*TG - 0.61*apoA-I (in mg/
dL).
Wagner (LDL-W), also including apoB levels in the for-
mula for the estimation of LDL-C concentration [20]
LDL-W = 0.358*TC + 0.776*apoB - 0.149*TG (in mg/dL).
Lipoprint System (LDL-L) [25, 26]
The estimation of LDL-C levels was provided by the LDL
Lipoprint System, which calculates LDL-C as the sum of
the cholesterol carried on IDL and LDL particles. It should
be noted that the LDL Lipoprint LDL System's use is not
intended for the evaluation of LDL-C levels rather than for
the estimation of the cholesterol carried on small, dense
LDL (sdLDL) particles, as well as for the estimation of
mean LDL particle size.
The mean LDL particle size (in Å) was provided by the
LDL Lipoprint System [25]. The ratio LDL-C/LDL-apoB (a
proposed index for the estimation of LDL particle size)
was calculated according to the formula proposed by Hat-
tori as follows :
LDL-H/LDL-apoB = LDL-H/(apoB-0.09*TC+0.09*HDL-
C-0.08*TG) (all lipid constituents measured in mg/dL).
Statistical analysis
Data are expressed as mean ± SD, except for parameters
not following a Gaussian distribution which are expressed
AS median (range). Preliminary analysis was performed
to ensure no violation of the assumptions of normality
and linearity. The Shapiro-Wilk test was used to evaluate
whether each variable followed a Gaussian distribution.
The relationships between different LDL-C estimationsLipids in Health and Disease 2006, 5:8 http://www.lipidworld.com/content/5/1/8
Page 6 of 7
(page number not for citation purposes)
were investigated using Pearson product-moment correla-
tion coefficient. Independent samples t-test (or Mann-
Whitney U test when appropriate) was used to assess dif-
ferences in the various LDL-C estimations as well in the
differences and biases of the LDL-calculations in the study
groups. One-way analysis of variance (ANOVA) followed
by Least Significant Difference (LSD) for paired compari-
sons were conducted in order to evaluate differences
between LDL-C estimations in the total cohort, as well as
within each study group. Analysis of covariance
(ANCOVA) was performed to evaluate the impact of TG
levels on the LDL-C estimations. The sensitivity of LDL-H/
LDL-apoB ratio at the specified cut-off point of 1.2 was
calculated as: [true positives/(true positives+ false nega-
tives)]*100, where "true positives" means the number of
patients with mean LDL particle size ≤ 268Å correctly clas-
sified by the LDL-H/LDL-apoB ratio and "false negatives"
means the number of patients with mean LDL particle size
≤ 268Å misclassified by the ratio. The specificity of the
previously mentioned ratio at the cut-off point of 1.2 was
calculated as [true negatives/(true negatives + false posi-
tives)]*100, where "true negatives" means the number of
patients with mean LDL particle size >268Å correctly clas-
sified by the LDL-H/LDL-apoB ratio and "false positives"
means the number of patients with mean LDL particle size
>268Å misclassified by the ratio. The positive and nega-
tive predictive values at the specified cut-off point of 1.2
were calculated as [true positives/(true positives + false
positives)]*100 and [true negatives/(true negatives + false
negatives)]*100, respectively. A p value of <0.05 was con-
sidered to be significant. All analyses were carried out with
the SPSS 13.0 softpack.
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